Why Novartis Is Paying $8.7 Billion for a Gene Therapy Developer You’ve Never Heard Of – Fortune
Fortune |
Why Novartis Is Paying $8.7 Billion for a Gene Therapy Developer You've Never Heard Of
Fortune On Monday, Novartis CEO Vasant Narasimhan announced the company would buy the Illinois-based gene–therapy developer AveXis for $8.7 billion. The acquisition comes only a few months into Narasimhan's tenure as CEO. AveXis's main drug treats spinal … Novartis enters deal to acquire gene therapy company AveXis for $8.7 billion Novartis Bets $8.7 Billion on Gene–Therapy Company Novartis buying gene therapy company AveXis for $8.7 billion |
